24/7 Market News Snapshot 18 February, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)

February 18, 2025

DENVER, Colo., 18 February, 2025 (247marketnews.com) – (NASDAQ:POAI) are discussed in this article.
Predictive Oncology Inc. is witnessing a notable surge in its stock, with pre-market shares trading at $1.726, reflecting an increase of 6.54% from the previous close of $1.620. The impressive trading volume of 1.13 million shares underscores robust investor interest, hinting at sustained momentum possibly linked to favorable market sentiment and advancements within the company’s innovative predictive analytics for oncology. Traders are advised to pay close attention to key resistance and support levels to determine potential price trajectories in this dynamic market environment.

The company has also made significant progress in its drug repurposing initiatives, unveiling promising compounds aimed at treating ovarian and other forms of cancer. Employing advanced artificial intelligence alongside a comprehensive drug database, Predictive Oncology is distinguishing itself in the cancer treatment landscape. The firm has undertaken extensive evaluations of pharmaceuticals previously overlooked or abandoned by larger entities, resulting in a catalog of candidates primed for clinical investigation.

In a recent statement, Dr. Arlette Uihlein, Senior Vice President of Translational Medicine and Drug Discovery, emphasized the efficiency of their AI-driven platform, which has adeptly identified numerous compounds showing potential efficacy across various tumor types. “Within just eight weeks of operation, our model has not only amplified our output tenfold but has also accelerated timelines traditionally required for laboratory assessments,” she noted.

Encouraging preliminary findings illustrate that two identified drugs have surpassed existing treatment outcomes in colon cancer, highlighting the transformative possibilities inherent in their research. Furthermore, Predictive Oncology is actively seeking to identify FDA-approved medications that exhibit promising effects in ovarian cancer, reinforcing its dedication to hastening the delivery of effective treatments.

As the market for repurposed pharmaceuticals is anticipated to expand from $32.1 billion in 2023 to $51.8 billion by 2033, Predictive Oncology is well-positioned to lead in therapeutic development, ultimately facilitating cost-effective and timely solutions in the field of oncology.

Related news for (POAI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.